ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1217

The Problem of Pain in Rheumatology: Clinical Profiles Associated with Concomitant Diagnoses with Chronic Overlapping Pain Conditions

Fibromyalgia and Other Clinical Pain Syndromes Poster

1:00PM-3:00PM: Abstract Number: 1145

The Prostate Plays a Role in Serum Urate Levels and the Risk of Gout in Men

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1438

The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1191

The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1325

The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1313

The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1186

The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1239

The Utility of Dual-Energy Computed Tomography in the Diagnosis of Gout

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1551

The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1419

Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1430

Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1266

Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1549

Toward Safer Glucocorticoid Therapy

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1241

Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1167

Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages

Systemic Sclerosis and Related Disorders – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].